Amgen (NASDAQ:AMGN) Sets New 12-Month High After Strong Earnings

Amgen Inc. (NASDAQ:AMGN)’s stock price reached a new 52-week high during trading on Wednesday following a better than expected earnings announcement. The stock traded as high as $356.52 and last traded at $352.5970, with a volume of 598987 shares traded. The stock had previously closed at $338.59.

The medical research company reported $5.29 earnings per share for the quarter, beating the consensus estimate of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The firm had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. During the same quarter in the previous year, the business earned $5.31 EPS. The firm’s revenue for the quarter was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS.

Amgen Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be issued a $2.52 dividend. The ex-dividend date of this dividend is Friday, February 13th. This is an increase from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 annualized dividend and a yield of 2.7%. Amgen’s dividend payout ratio is currently 66.90%.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Q4 results beat Street estimates and management issued a robust 2026 outlook, driven by double‑digit revenue and EPS growth and strong new‑product uptake — a primary driver of the rally. Amgen Q4 results beat Street estimates
• Positive Sentiment: Several brokerages raised price targets (notably Goldman Sachs to $415 and RBC/Leerink upgrades), lending credibility to upside expectations and supporting institutional buying interest. Goldman Sachs adjusts price target on Amgen
• Positive Sentiment: Momentum indicators and flow show Amgen near 52‑week highs with reports of institutional accumulation, reinforcing sentiment that the company’s growth trajectory is being re‑rated. Amgen Stock Hits 52-Week Highs: Buy Signal?
• Neutral Sentiment: Amgen reported completion of postmarketing work on IMLYGIC’s melanoma safety study and updates on the FORTITUDE‑301 trial; these procedural milestones reduce uncertainty but are unlikely to move the needle until detailed data or regulatory actions follow. IMLYGIC safety study reaches completion
• Neutral Sentiment: Analyst coverage is mixed: some firms reiterate holds or lower relative targets even as others are bullish, creating a split narrative on valuation vs. execution risk. Analyst: new-product uptake offset by legacy erosion
• Negative Sentiment: CVS Health will remove Amgen and Lilly bone‑disease treatments from some preferred drug lists effective April 1, substituting lower‑cost alternatives — a clear near‑term sales headwind for affected products and a reason for investor caution. CVS to drop Amgen and Lilly bone disease treatments

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Leerink Partners upped their price target on shares of Amgen from $305.00 to $355.00 and gave the stock an “outperform” rating in a research note on Wednesday. Weiss Ratings restated a “buy (b)” rating on shares of Amgen in a research report on Monday, December 29th. Truist Financial lifted their price target on Amgen from $318.00 to $319.00 and gave the company a “hold” rating in a research report on Thursday, January 8th. Royal Bank Of Canada upped their price objective on Amgen from $335.00 to $360.00 and gave the company an “outperform” rating in a report on Wednesday. Finally, DZ Bank lifted their target price on Amgen from $335.00 to $364.00 in a report on Monday, November 10th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $347.65.

Insider Activity at Amgen

In other Amgen news, EVP Murdo Gordon sold 6,879 shares of the firm’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $336.83, for a total value of $2,317,053.57. Following the completion of the transaction, the executive vice president directly owned 41,923 shares in the company, valued at $14,120,924.09. This trade represents a 14.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, SVP Nancy A. Grygiel sold 3,139 shares of Amgen stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the completion of the transaction, the senior vice president directly owned 7,225 shares in the company, valued at approximately $2,436,703.50. This trade represents a 30.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 10,908 shares of company stock worth $3,674,966 in the last quarter. 0.76% of the stock is owned by company insiders.

Hedge Funds Weigh In On Amgen

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AMGN. Sequoia Financial Advisors LLC increased its position in shares of Amgen by 2.3% in the third quarter. Sequoia Financial Advisors LLC now owns 160,646 shares of the medical research company’s stock worth $45,334,000 after purchasing an additional 3,619 shares during the period. Atlantic Union Bankshares Corp lifted its position in Amgen by 165.0% during the second quarter. Atlantic Union Bankshares Corp now owns 10,643 shares of the medical research company’s stock worth $2,972,000 after purchasing an additional 6,627 shares during the period. Davis Capital Management acquired a new stake in Amgen during the third quarter worth about $1,841,000. D.A. Davidson & CO. increased its holdings in Amgen by 2.6% in the 3rd quarter. D.A. Davidson & CO. now owns 243,054 shares of the medical research company’s stock valued at $68,590,000 after buying an additional 6,222 shares during the period. Finally, Global Wealth Management Investment Advisory Inc. raised its position in shares of Amgen by 56.2% in the 3rd quarter. Global Wealth Management Investment Advisory Inc. now owns 13,056 shares of the medical research company’s stock valued at $3,684,000 after buying an additional 4,699 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Stock Up 0.4%

The firm’s 50-day moving average price is $333.66 and its 200 day moving average price is $310.84. The company has a current ratio of 1.14, a quick ratio of 0.99 and a debt-to-equity ratio of 5.78. The company has a market capitalization of $198.05 billion, a price-to-earnings ratio of 25.85, a PEG ratio of 3.20 and a beta of 0.46.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.